Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06856694 · ClinicalTrials.gov registry record · NA

RCT of NLP-Based Feedback for Improving SDM in Men With Localized Prostate Cancer

A NA study of Prostate Cancer and Shared Decision Making, sponsored by Cedars-Sinai Medical Center.

Recruiting
Registry status
NA
Development phase
283
Enrollment target
1
Study location

NCT06856694 is a NA study of Prostate Cancer and Shared Decision Making that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 283 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06856694, a NA study of Prostate Cancer and Shared Decision Making, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.

RECRUITING
Registry status
NA
Development phase
283 participants
Enrollment target
1
Study location

Study Summary

The purpose of the research is to assess the impact of a natural language processing + artificial intelligence (NLP+AI)-based risk communication feedback system to improve quality of risk communication of key tradeoffs during prostate cancer consultations among physicians and to improve patient decision making. In this cluster randomized trial, an evaluable 259 patients with newly diagnosed clinically localized prostate cancer will be cluster randomized within an evaluable 24 physicians to: 1. a control arm, in which patients will receive standard of care treatment consultations along with AUA-endorsed educational materials on treatment risks and benefits (for patients) and on SDM (for physicians) or 2. an experimental arm, in which patients and participating physicians will receive NLP+AI-based feedback on what was said about key tradeoffs within approximately 72 hours of the consultation to assist with decision making. Physicians will additionally be provided with grading of their risk communication for each visit based on an a priori defined framework for quality of risk communication and recommendations for improvement. In both study arms, there will be an audio-recorded follow-up phone or video call between the physician and patient to allow for further discussion of risk and clarifying any areas of ambiguity, which will be qualitatively analyzed to see if areas of poor communication were rectified. After the follow-up phone call, patients and participating physicians will be asked to complete a very brief survey about their experience. The study plans to test whether receiving NLP+AI-based feedback improves decisional conflict, shared decision making, and appropriateness of treatment choice over the standard of care in patients undergoing treatment consultations for prostate cancer. Study staff will also test whether providing feedback and grading of risk communication to physicians affects quality of physician risk communication, since providing feedback w

Interventions

  • OTHER NLP+AI Report

Study Locations (1)

California

  • Cedars Sinai Medical Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 283 participants
Start Date 2025-10-22
Est. Completion 2029-12
Phase NA

Sponsor

Cedars-Sinai Medical Center

339 total trials

What the Registry Record Tells You About NCT06856694

The ClinicalTrials.gov registry entry for NCT06856694 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 283 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (53% lower). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which NLP+AI Report is the first listed.

NCT06856694 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06856694 about?

NCT06856694 is a clinical study titled "RCT of NLP-Based Feedback for Improving SDM in Men With Localized Prostate Cancer". The purpose of the research is to assess the impact of a natural language processing + artificial intelligence (NLP+AI)-based risk communication feedback system to improve quality of risk communication of key tradeoffs during prostate cancer consultations among physicians and to improve patient deci...

What is the current status of trial NCT06856694?

This trial is currently recruiting. It is a NA study. The enrollment target is 283 participants. The study started on 2025-10-22. Estimated completion is 2029-12.

What conditions does trial NCT06856694 study?

This clinical trial studies the following conditions: Prostate Cancer, Shared Decision Making, Risk Communication.

What interventions are being tested in trial NCT06856694?

The interventions under investigation include: NLP+AI Report (OTHER).

Who is sponsoring clinical trial NCT06856694?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06856694 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.